IASLC Newsletter - August 2018

In the last 20 years, the decision-making process of the entire thoracic oncology community has been influenced by several windstorms that profoundly modified our diagnostic and therapeutic strategies.

IASLC Newsletter - July 2018

Our annual meeting, the IASLC 19th World Conference on Lung Cancer (WCLC 2018), is quickly approaching

Subsolid nodules (SSN) can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance.

By 2030, the number of deaths attributed to lung cancer is expected to double for Latin American women and increase by 50% for men.

IASLC Newsletter - June 2018

Newer treatment options, biomarker-based patient segmentation and the availability of biomarker-based treatment approaches have added to treatment complexity over the years.

The International Association for the Study of Lung Cancer (IASLC) announces a significant jump in the 2017 Impact Factor of the Journal of Thoracic Oncology (JTO) to 10.336, up from 6.595 in 2016.